Navigating the Rapids : The Development of NGS-based Clinical Trial Assays and Companion Diagnostics
Over the past decade, next generation sequencing (NGS) technology has experienced meteoric growth in the aspects of platform, technology and supporting bioinformatics development allowing its widespread and rapid uptake in research settings. More recently, NGS-based genomic data has been exploited...
Main Authors: | Saumya ePant, Russell eWeiner, Matthew John Marton |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00078/full |
Similar Items
-
Companion Diagnostics for Targeted Cancer Drugs - Clinical and Regulatory Aspects
by: Dana eOlsen, et al.
Published: (2014-05-01) -
How are we evaluating the cost-effectiveness of companion biomarkers for targeted cancer therapies? A systematic review
by: Mikyung Kelly Seo, et al.
Published: (2021-09-01) -
Personalized medicine: biomarkers and companion diagnostics
by: Renato Bernardini, et al.
Published: (2018-03-01) -
Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2
by: Ken Uchibori, et al.
Published: (2021-03-01) -
The current landscape of the FDA approved companion diagnostics
by: Jan Trøst Jørgensen
Published: (2021-06-01)